Latest content

  • Put your challenging affinity screening campaigns back on track — after you’ve tried everything else37:25

    Put your challenging affinity screening campaigns back on track — after you’ve tried everything else

    When you’re entrusted with developing therapeutics for challenging or undruggable targets, it’s a struggle to characterize molecular interactions. And it’s not for lack of effort or expertise — SPR an

    Watch
  • NanoTemper announces Monolith X with breakthrough Spectral Shift technology, enabling affinity measurements where other methods fail

    NanoTemper announces Monolith X with breakthrough Spectral Shift technology, enabling affinity measurements where other methods fail

    NanoTemper Technologies introduced Monolith X, adding breakthrough Spectral Shift technology to their top-selling Monolith product line.

    Read
  • Introducing Monolith X - the only way to get binding affinities in solution using very minimal sample2:20

    Introducing Monolith X - the only way to get binding affinities in solution using very minimal sample

    Watch
  • The only way to get binding affinities in solution using very minimal sample

    The only way to get binding affinities in solution using very minimal sample

    Read
  • Select the best biologics candidates with high-quality, multi-parameter stability characterization

    Select the best biologics candidates with high-quality, multi-parameter stability characterization

    Read
  • Learn the pros and cons of these 3 methods to serotype your AAV gene therapy vectors

    Learn the pros and cons of these 3 methods to serotype your AAV gene therapy vectors

    Read
  • ×

    Sign up to receive
    the latest NanoTemper news, product updates, event announcements and more

    First Name
    Last Name
    Company Name
    Country
    State
    Province
    State
    Region
    State
    Canton
    Agree to Subscribe & Privacy Policy*
    *I have fully read, understood and agree to the Privacy Policy. I accept the storing and processing of my personal data by NanoTemper as described in the Privacy Policy.

    By completing this form, you provide us consent to contact you with educational content, news and information about our products, services and events. You may unsubscribe at any time.
    Thank you!
    Error - something went wrong!
  • 5 benefits of optimizing your formulation buffer to get your AAV therapeutic approved

    5 benefits of optimizing your formulation buffer to get your AAV therapeutic approved

    As a gene therapy scientist, you face an abundance of challenges when working to build an effective AAV therapeutic. Many steps of the development workflow have yet to be standardized and the...

    Read
  • Characterize your PROTAC hook effect with flexible and in-solution affinity measurements for results you can trust

    Characterize your PROTAC hook effect with flexible and in-solution affinity measurements for results you can trust

    Read
  • Serotyping: why, when, and how to assess your AAV therapeutic to get it approved14:07

    Serotyping: why, when, and how to assess your AAV therapeutic to get it approved

    When you develop an AAV therapeutic, you need to assess many key parameters, or Critical Quality Attributes (CQAs), in order to track progress and, ultimately, get your therapeutic approved. As part

    Watch
  • Contact Specialist
  • Rely on Dianthus to overcome roadblocks in your PROTAC characterizations

    Rely on Dianthus to overcome roadblocks in your PROTAC characterizations

    Read
  • NanoTemper Technologies welcomes Andreas Schmitz as its first Chief Human Resources Officer

    NanoTemper Technologies welcomes Andreas Schmitz as its first Chief Human Resources Officer

    MUNICH, Germany, 18 May 2022 — NanoTemper Technologies, well-known for creating biophysical tools that tackle challenging characterizations, welcomes Andreas Schmitz as the first Chief Human...

    Read
  • 8 Gene Therapy conferences you should attend in 2022

    8 Gene Therapy conferences you should attend in 2022

    With the first AAV-based gene therapies approved, and new gene editing strategies emerging, it’s important to stay on top of the latest topics in this therapeutic area. Here are 8 gene therapy...

    Read
  • 9 Targeted Protein Degradation conferences you don’t want to miss in 2022

    9 Targeted Protein Degradation conferences you don’t want to miss in 2022

    With so much interest and investment in target protein degradation, a lot can happen in a year. Here are 9 conferences to get up-to-date on recent progress and the latest approaches. You’ll not...

    Read
  • Get more information about your protein expression conditions in less time with Andromeda

    Get more information about your protein expression conditions in less time with Andromeda

    Get more information about your protein expression conditions in less time with Andromeda

    Read
  • Ways light scattering technologies help you if you’re in gene therapy

    Ways light scattering technologies help you if you’re in gene therapy

    Read
  • Four technologies to profile your AAVs

    Four technologies to profile your AAVs

    Read
  • NanoTemper Technologies and PharmAI launch Proto, a free AI tool to quickly determine optimal protein labeling strategy

    NanoTemper Technologies and PharmAI launch Proto, a free AI tool to quickly determine optimal protein labeling strategy

    MUNICH/DRESDEN, April 6, 2022—NanoTemper Technologies, in partnership with PharmAI, announced the launch of Proto, a free AI-based web application that reveals the best labeling strategy to help...

    Read
  • 10 terms to help you more easily understand targeted protein degradation

    10 terms to help you more easily understand targeted protein degradation

    Targeted Protein Degradation (TPD), a relatively new therapeutic approach, is making waves by targeting otherwise ‘undruggable’ proteins. PROTACs are the best-understood protein degraders, with...

    Read
  • NanoTemper Technologies launches Spectral Shift, a breakthrough technology that changes the game for affinity-based screenings

    NanoTemper Technologies launches Spectral Shift, a breakthrough technology that changes the game for affinity-based screenings

    NanoTemper Technologies, announced today the launch of Spectral Shift technology within their Dianthus instrument, built to handle the most challenging affinity-based screenings in drug discovery....

    Read
  • Finally tackle your most challenging affinity screenings with breakthrough Spectral Shift technology with Dianthus

    Finally tackle your most challenging affinity screenings with breakthrough Spectral Shift technology with Dianthus

    Read
  • loading
    Loading more...